Risk prediction for clonal cytopenia: multicenter real-world evidence
Key Points
A 3-parameter CCRS model was devised specifically for patients diagnosed with clonal cytopenia.
patient
What have we learned about TP53-mutated acute myeloid leukemia?
Abstract
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
Key Points
This study illustrates the survival benefits of abatacept combined with CNI/MTX in patients with hematologic malignancies undergoing HCT.
The addition of abatacept may provide an approach for alternative donor pool expansion when HLA-identical sibling donors are unavailable.
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition
Abstract
Manuel Espinoza Gutarra, MD
Espinoza Gutarra, Manuel
Assistant Professor of Medicine
University of Alabama Birmingham
Kah Poh (Melissa) Loh, MBBCh BAO, MS, FACCC
Loh, Kah Poh
Assistant Professor of Medicine
University of Rochester
Online Profile:
High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations
This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038
(pdf available at link)
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial
Summary
Background
Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population.
Methods
Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology
Several national agencies, including the American Society of Clinical Oncology (ASCO), recommend the prescription of exercise for patients diagnosed with cancer.1,2 The evidence base for this recommendation is derived from studies that showed exercise-related improvements in patient-reported outcomes (PROs), treatment-associated adverse effects, cardiorespiratory fitness (CRF), and overall physical functioning.3-6 Additionally, exercise may have direct anticancer effects and indirect effects by synergizing standard cancer therapies.7,8 Despite these benefits, the implementation of exercise